Iomai Corporation (Nasdaq: IOMI) today announced interim results from a Phase 1 clinical trial of its patch-based vaccine for seasonal influenza. The company will hold a conference call at 8:30 a.m. Eastern Time today to discuss the results. The 353-patient study compared the immune responses generated by Iomai's needle-free vaccine patch and an injected intramuscular vaccine. [click link for full article]
More...